Drug Profile
Research programme: monoclonal antibody therapeutics - Igenica
Alternative Names: IGN 381; IGN 786Latest Information Update: 07 Jun 2017
Price :
$50
*
At a glance
- Originator Igenica
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Checkpoint kinase inhibitors; Surface antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 24 May 2017 Pierre Fabre acquires monoclonal antibody therapeutics from Igenica
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)